PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsElagolix
Elagolix
Oriahnn, Orilissa (elagolix) is a small molecule pharmaceutical. Elagolix was first approved as Orilissa on 2018-07-23. It is used to treat abdominal pain in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Orilissa
Combinations
Oriahnn
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Elagolix sodium
+
Elagolix sodium
+
Estradiol
+
Norethindrone acetate
Tradename
Company
Number
Date
Products
ORIAHNN (COPACKAGED)AbbVieN-213388 RX2020-05-29
1 products, RLD, RS
Elagolix sodium
Tradename
Company
Number
Date
Products
ORILISSAAbbVieN-210450 RX2018-07-23
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
oriahnnNew Drug Application2023-06-05
orilissaNew Drug Application2023-06-05
orlissaNew Drug Application2018-07-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
menorrhagiaEFO_0003945D008595N92.0
acne vulgarisEFO_0003894D000152L70
endometriosisEFO_0001065D004715N80
endometrial hyperplasia—D004714N85.0
abdominal painHP_0002027D015746R10.9
hypogonadismHP_0000044D007006E23.0
Agency Specific
FDA
EMA
Expiration
Code
ELAGOLIX SODIUM, ORILISSA, ABBVIE
2023-07-23NCE
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE / ELAGOLIX SODIUM, ORIAHNN (COPACKAGED), ABBVIE
2023-07-23NCE
2023-05-29NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Elagolix Sodium, Orilissa, Abbvie
115422392039-07-23DS, DP
105375722036-09-01U-2735
106823512036-09-01U-2850
113445512034-03-14U-3388, U-3389
70569272024-09-10DS, DP
71762112024-07-06U-2360
74199832024-07-06DS, DPU-2360
Elagolix Sodium,Estradiol,Norethindrone Acetate / Elagolix Sodium, Oriahnn (Copackaged), Abbvie
108816592034-03-14U-2842
110454702034-03-14U-2842
114593052028-11-07DPU-2842
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CC: Anti-gonadotropin-releasing hormones
— H01CC03: Elagolix
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeiomyomaD007889HP_0000131D25—241411
MyofibromaD047708———241310
MenorrhagiaD008595EFO_0003945N92.0—24129
HemorrhageD006470MP_0001914R58—24118
AnovulationD000858—————1—1
AdenomaD000236—————1—1
Adrenocortical adenomaD018246—————1—1
Cushing syndromeD003480EFO_0003099E24———1—1
Cerebrovascular disordersD002561EFO_0003763I60-I69———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EndometriosisD004715EFO_0001065N802711—323
InfertilityD007246HP_0000789—112——4
DysmenorrheaD004412HP_0100607N94.6——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Uterine hemorrhageD014592———2———2
Polycystic ovary syndromeD011085EFO_0000660E28.2—1———1
SyndromeD013577———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318HP_0001626—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameElagolix
INNelagolix
Description
Elagolix is an organooxygen compound and an organonitrogen compound. It is functionally related to a gamma-amino acid.
Classification
Small molecule
Drug classgonadotropin releasing hormone (GnRH) receptor antagonists (nonpeptide)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F
Identifiers
PDB—
CAS-ID834153-87-6
RxCUI—
ChEMBL IDCHEMBL1208155
ChEBI ID—
PubChem CID11250647
DrugBankDB11979
UNII ID5B2546MB5Z (ChemIDplus, GSRS)
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
2798
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Q92644
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Oriahnn – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 422 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oriahnn
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,033 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use